How to Write the NU553 Unit 9 Assignment
A direct, section-by-section guide for nursing students working through the NU553 Unit 9 template — covering what to write in every essay section, how to complete the six-drug table, and what the rubric is really testing.
💊 Need expert help with your NU553 Unit 9 assignment? Our nursing pharmacology specialists can guide you through every section.
Get Expert Help →What This Assignment Is Actually Testing
NU553 Unit 9 asks you to apply pharmacodynamic and pharmacokinetic principles to pain management, then document your analysis in a two-part template: a short essay with nine specific headers, and a six-column drug table covering acetaminophen, NSAIDs, opioids, anticonvulsants, skeletal muscle relaxants, and cannabis. The rubric rewards clinical precision, accurate terminology, and a clear understanding of how each drug class works — not length.
The assignment is shorter than it looks. Each essay section only needs 2–4 sentences. The table wants bullet points, not paragraphs. The mistake most students make is overwriting — pasting textbook chunks instead of synthesizing what they actually know into clean, specific clinical statements.
The other mistake is treating the table as a separate task from the essay. They’re connected. Your essay introduces the concepts; the table applies them to specific drugs. Morphine, for example, should model everything you said about opioid pharmacokinetics in the essay. That coherence is what an organized, well-integrated submission looks like.
Essay Component
9 sections with bolded headers, 2–4 sentences each. Covers pharmacodynamics, pharmacokinetics, MOA, legal/ethical, policy, assessment, and non-pharm therapies.
Drug Table
6 columns, one drug per class. Each column covers brand/generic name, indications, MOA, dosage, duration, contraindications, monitoring, and goals.
Legal & Ethical
Controlled substance prescribing law, PDMP requirements, informed consent, and the balance between therapeutic access and misuse prevention.
Format Rules
Arial 10pt in the table. APA 7th edition references. Bolded section headers in the essay. Citations can appear under drug names in the table columns.
Before You Write Anything
Download the NU553 Unit 9 template from your course materials and keep it open as you work through this guide. This guide mirrors the template’s headers section by section. Every drug you choose for the table should be one you can find in your course textbook (Rosenthal & Burchum’s Lehne’s Pharmacology for Nursing Care is the standard NU553 text) — because your citations need to support specific, accurate clinical claims, not general web summaries.
How to Write Each Essay Section
Nine headers. 2–4 sentences per section. That’s the whole essay. The challenge isn’t filling space — it’s being precise enough in a short space that every sentence carries real clinical information. Here’s what each section actually requires.
Introduction to Pain Management Therapies
This is your framing paragraph. Introduce pain as a clinical problem: its prevalence, the fact that it is underassessed and undertreated, and the multimodal approach that evidence supports. Mention that pain management involves multiple drug classes — each acting through distinct mechanisms — plus non-pharmacological adjuncts. One sentence should acknowledge the complexity of balancing efficacy, safety, and the regulatory environment around controlled substances. Avoid vague openers like “Pain is a common problem.” Start with something clinically grounded, for example: “Chronic pain affects approximately 20% of adults in the United States and represents one of the most complex therapeutic challenges in clinical practice, requiring individualized assessment and multimodal treatment strategies that span pharmacological and non-pharmacological approaches.”
Pharmacodynamics
Define pharmacodynamics clearly — it is the study of what a drug does to the body, including receptor binding, signal transduction, and downstream physiological effects. Then apply this specifically to pain management. A strong 2–4 sentence section might: define PD, explain how different drug classes produce analgesia at the receptor level (e.g., opioids at mu-opioid receptors; NSAIDs via COX-1/COX-2 inhibition), and name one specific example. For example: “Pharmacodynamics refers to the mechanisms by which a drug produces its biological effects within the body. In pain management, opioids exert their analgesic action by binding to mu-opioid receptors in the central and peripheral nervous system, inhibiting ascending pain transmission and activating descending inhibitory pathways. The pharmacodynamic profile of a drug determines not only its analgesic efficacy but also its side effect burden and therapeutic window.”
Pharmacokinetics
Define pharmacokinetics — what the body does to the drug — using the ADME framework (absorption, distribution, metabolism, excretion). Apply it to pain management with a specific example. Good candidates: morphine’s hepatic first-pass effect explaining why oral doses are higher than IV doses; gabapentin’s renal clearance and dose adjustment in kidney disease; acetaminophen’s cytochrome P450 metabolism and why hepatic impairment matters. Keep it tight. Don’t list all four ADME elements for every drug class — pick one that illustrates a clinically important principle and state it precisely.
Mechanism of Actions
This section bridges PD theory to clinical classes. State that different pain management drug classes work through distinct mechanisms, then give 2–3 examples that preview your table. Opioids: activate mu-opioid receptors → suppress pain signaling. NSAIDs: inhibit cyclooxygenase enzymes → reduce prostaglandin synthesis → decrease peripheral sensitization. Anticonvulsants like gabapentin: bind to voltage-gated calcium channels → reduce neurotransmitter release in the dorsal horn. Cannabis: acts on CB1 and CB2 endocannabinoid receptors. Keep this section mechanism-focused, not indication-focused — the table covers indications.
Prescribing Considerations
This is a clinical judgment section. Address the factors that shape drug selection in pain management: pain type (nociceptive vs. neuropathic vs. mixed), patient comorbidities (renal/hepatic function, cardiovascular risk, substance use history), concurrent medications and drug interactions, and route of administration. You can also note the principle of multimodal analgesia — combining drugs with complementary mechanisms to achieve adequate pain control with lower doses of each, reducing adverse effects. This section is short, so pick 2–3 of the most clinically important considerations and state them precisely.
Legal / Ethical Factors
See the full section below on legal and ethical considerations — this deserves careful treatment because it’s one of the areas where students lose marks by being too vague. The key elements: DEA Schedule II classification and what it restricts, state PDMP requirements, informed consent obligations, the ethical tension between pain relief and addiction risk, and equitable prescribing across patient populations. 2–4 sentences, specific to controlled substance prescribing.
Policy
Name specific policies — the DEA Controlled Substances Act, state PDMP requirements, and CDC opioid prescribing guidelines. You can reference the 2022 CDC Clinical Practice Guideline for Prescribing Opioids (updated from the 2016 version) as a current, relevant policy document. Note any institutional policies, such as quantity limits or mandatory PDMP checks before prescribing. Avoid generic statements like “nurses must follow policy.” Name the actual policies and state what they require.
Pain Assessment Tools
See the full section below on assessment tools. Name at least 2–3 specific validated tools, including their appropriate clinical context. The NRS (Numeric Rating Scale) is the minimum — but a strong answer also names CPOT for non-verbal patients, the McGill Pain Questionnaire for multidimensional assessment, and possibly the BPI (Brief Pain Inventory) for functional impact. Note that assessment informs prescribing and monitoring, not just documentation.
Nonpharmacological Therapies
List evidence-based non-pharmacological pain interventions and briefly state their mechanism or evidence base. Physical therapy and exercise (reduces sensitization, improves function); cognitive behavioral therapy (modifies pain catastrophizing and maladaptive responses); TENS (transcutaneous electrical nerve stimulation, activates gate control mechanism); heat/cold therapy; acupuncture (evidence base modest but growing); mindfulness-based stress reduction (MBSR, shown to reduce pain intensity in chronic pain populations). Briefly note that these work best as adjuncts in a multimodal approach, not standalone replacements for pharmacotherapy in moderate-severe pain.
Two to four sentences per section means precision, not padding. Every sentence should carry a specific clinical claim — a drug name, a receptor, a policy, a tool, a mechanism. If you can remove a sentence without losing clinical information, remove it.
— Core principle of concise clinical academic writingCompleting the Six-Drug Table
The table has six drug class columns. You pick one specific drug per class. The rubric says to put the drug name under the class name. Below is guidance on what drug to choose and what to include in each row — based on what is well-documented, available in standard pharmacology texts, and straightforward to write about accurately.
Column 1: Acetaminophen
Recommended drug: Acetaminophen (Tylenol)
- Indications: Mild to moderate pain, osteoarthritis, fever reduction; first-line for many pain conditions due to safety profile
- MOA: Not fully established; inhibits prostaglandin synthesis centrally, possible modulation of endocannabinoid system; does NOT significantly inhibit COX peripherally (distinguishes it from NSAIDs)
- Dosage key point: Max 4g/day in healthy adults; 2g/day in hepatic impairment or heavy alcohol use; available in oral, rectal, IV forms
- Duration: 4–6 hours per dose
- Major contraindication/warning: Hepatotoxicity at overdose; common hidden source in combination products (hydrocodone/acetaminophen)
- Monitoring/Goals: Monitor liver function in long-term use or at-risk patients; goal is pain NRS reduction ≥2 points with preserved functional status
Column 2: NSAID
Recommended drug: Ibuprofen (Advil/Motrin)
- Indications: Mild-moderate pain, inflammatory conditions (arthritis, dysmenorrhea), fever; also used adjunctively in post-operative pain protocols
- MOA: Nonselective inhibition of COX-1 and COX-2 → reduces prostaglandin and thromboxane synthesis → decreased peripheral sensitization and inflammation
- Dosage: 200–800mg orally every 4–6 hours; max 3,200mg/day (prescription); 1,200mg/day OTC
- Duration: 4–6 hours
- Contraindications: Renal impairment (reduces renal prostaglandins), active peptic ulcer disease, post-CABG surgery, concurrent anticoagulant use; GI prophylaxis with PPI often recommended in high-risk patients
- Monitoring/Goals: BMP (renal function, especially in elderly); GI symptom monitoring; goal: reduce inflammatory pain with functional improvement; avoid long-term high-dose use
Column 3: Opioid
Recommended drug: Morphine sulfate (MS Contin / MSIR)
- Indications: Moderate-to-severe pain, including post-surgical, cancer-related, and palliative pain; dyspnea in end-stage illness
- MOA: Full agonist at mu-opioid receptors in CNS and periphery → inhibits ascending pain signals, activates descending inhibition, alters emotional processing of pain
- Dosage: IR: 5–30mg oral every 4 hours; ER (MS Contin): 15–200mg every 8–12 hours; IV/subcutaneous doses are significantly lower due to first-pass avoidance
- Duration: IR: 3–5 hours; ER formulations: 8–12 hours
- Contraindications/Warnings: Respiratory depression (especially with concurrent CNS depressants or benzodiazepines); renally impaired patients accumulate active metabolite (morphine-6-glucuronide) → toxicity risk; constipation universal — prophylactic bowel regimen required; physical dependence with prolonged use
- Monitoring/Goals: NRS pain scores before/after administration; respiratory rate and sedation level; PDMP check before prescribing; COWS/CIWA scale if monitoring for withdrawal; ORT (Opioid Risk Tool) before initiating; goal: functional pain control (≤4/10) with preserved respiration and minimal sedation; individualized tapering plan documented
Note: Morphine is Schedule II. PDMP query required in all US states before prescribing. No refills on Schedule II prescriptions — new prescription required each time.
Column 4: Anticonvulsant
Recommended drug: Gabapentin (Neurontin)
- Indications: Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), fibromyalgia, adjunct in multimodal analgesia; originally indicated for seizures
- MOA: Binds alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn → reduces calcium influx → decreases release of excitatory neurotransmitters (glutamate, substance P, norepinephrine) → dampens central sensitization
- Dosage: Start 300mg at bedtime; titrate to 300–600mg three times daily; max 3,600mg/day; renally dosed — CrCl-based dosage adjustment required
- Duration: 8 hours per dose; dose-dependent effect builds with titration over days to weeks
- Contraindications/Warnings: Renal impairment requires dose reduction; sedation and dizziness (fall risk in elderly); CNS depression potentiated by opioids — increasingly co-regulated in some states; abrupt discontinuation can trigger withdrawal/seizure
- Monitoring/Goals: Renal function (BMP); sedation and fall risk assessment; pain diary/NRS tracking; goal: reduction in neuropathic pain symptoms with tolerable side effects; Neuropathic Pain Scale (NPS) or DN4 questionnaire useful for characterizing and tracking response
Column 5: Skeletal Muscle Relaxant
Recommended drug: Cyclobenzaprine (Flexeril)
- Indications: Acute musculoskeletal pain with spasm; short-term adjunct (generally ≤2–3 weeks); not appropriate for spasticity of CNS origin
- MOA: Structurally similar to tricyclic antidepressants; acts primarily in the brain stem to reduce tonic somatic motor activity → reduces muscle spasm; not a direct peripheral muscle relaxant
- Dosage: 5–10mg orally three times daily; IR formulation; max 60mg/day; ER (Amrix) 15–30mg once daily
- Duration: 12–24 hours; half-life 18 hours — significant accumulation risk with repeated dosing, especially in elderly
- Contraindications/Warnings: Avoid in patients taking MAOIs (serotonin syndrome risk); not for long-term use; anticholinergic effects (dry mouth, urinary retention, constipation); Beers Criteria — avoid in older adults due to CNS effects and fall risk
- Monitoring/Goals: Pain and functional assessment (PROMIS pain interference scale or NRS); monitor for sedation; short-term use documentation; goal: resolution of acute spasm with return to functional baseline; reassess at 1–2 weeks
Column 6: Cannabis
Recommended drug: Dronabinol (Marinol) — FDA-approved synthetic THC
- Indications: Nausea/vomiting from chemotherapy (primary FDA indication); anorexia in AIDS; used off-label for pain in states with medical cannabis programs; dronabinol allows discussion of a federally legal cannabis-based agent
- MOA: Partial agonist at CB1 receptors (CNS — pain modulation, psychoactive effects) and CB2 receptors (immune cells, peripheral nervous system — anti-inflammatory effects); modulates endocannabinoid system which regulates pain, inflammation, and mood
- Dosage: Dronabinol: 2.5–10mg orally 2–4 times daily; highly variable bioavailability (10–20%); onset 0.5–1 hour; if using medical cannabis content generally, note that formulation, potency, and route vary widely — standardization is a major clinical challenge
- Duration: 4–6 hours psychoactive effects; metabolites detectable up to weeks
- Contraindications/Warnings: Psychosis or schizophrenia history; severe cardiovascular disease; substance use disorder (especially cannabis use disorder); impaired driving; Schedule III (dronabinol) or Schedule I (raw cannabis at federal level) — legal complexity varies by state
- Monitoring/Goals: NRS or PGIC (Patient Global Impression of Change); mood and cognitive monitoring; urine drug screening; respiratory assessment if inhaled forms used; goal: reduce pain burden and improve function without significant psychoactive adverse effects; evidence strongest for neuropathic and cancer-related pain (Aviram & Samuelly-Leichtag, 2017)
Table Formatting Reminders
- Font: Arial 10pt throughout the table — do not let Word auto-change it
- Content: bulleted key points, not full paragraphs — keep each cell concise
- Citations: place under the drug name in the class column, or in the reference page — both are acceptable per the instructions
- The last row (Monitoring / Goals / Assessment Scale) is the most frequently underwritten section — name the actual tool (NRS, CPOT, ORT, NPS) and state the specific therapeutic goal
Legal and Ethical Considerations for Controlled Substance Prescribing
This is one of the sections where students consistently underwrite. “Nurses must follow legal and ethical guidelines” is not a legal/ethical consideration — it’s a sentence that says nothing. Here’s what the section actually needs to address.
Legal Framework
The Controlled Substances Act (21 U.S.C. § 801 et seq.) is the federal law governing prescribing, dispensing, and monitoring of controlled substances in the United States. It creates five schedules based on accepted medical use and abuse potential. Schedule II drugs — which include morphine, oxycodone, fentanyl, hydromorphone, and methylphenidate — have high abuse potential and accepted medical use, but no authorized refills. A new prescription is required each time. Prescribers must hold a valid DEA registration and comply with state-specific additional requirements, which in many states exceed federal minimums.
The Ryan Haight Online Pharmacy Consumer Protection Act restricts online prescribing of controlled substances, requiring at least one in-person evaluation before an opioid can be prescribed — a regulation with significant telemedicine implications that became acutely relevant during COVID-19 telehealth expansions.
Ethical Tensions
Pain management presents some of the most clearly articulated ethical tensions in clinical nursing and medicine. The core tension is between:
Additional ethical considerations: informed consent requires that patients understand the risks of opioid therapy before initiating treatment, including addiction risk, interaction risks, and what withdrawal would involve. Equitable prescribing requires awareness of documented racial disparities in pain assessment and treatment. Prescriber moral distress — when clinical judgment and institutional or regulatory constraints conflict — is a real phenomenon that nursing and medical professionals report in pain management contexts.
What “Ethical Consideration” Actually Means in This Section
Your 2–4 sentences need to name a specific ethical issue and describe it in clinical terms. Don’t write: “It is important to be ethical when prescribing pain medications.” Do write: “Prescribers face an ethical obligation to balance adequate pain relief — guided by the principle of beneficence — against the documented risk of opioid use disorder, requiring individualized risk assessment tools such as the ORT (Opioid Risk Tool) before initiating Schedule II therapy and ongoing PDMP monitoring to detect early signs of misuse or diversion.”
Policies That Influence Prescribing Schedule II Medications
Name specific policies. Your essay section on policy should reference at least one by name. Here are the most relevant ones for this assignment:
| Policy / Guideline | What It Requires | Clinical Relevance |
|---|---|---|
| DEA Controlled Substances Act (Schedule II) | No refills; written or electronic prescription required; DEA registration mandatory for prescribers; quantity limits vary by state | Directly controls how morphine, oxycodone, fentanyl, etc. can be prescribed and dispensed |
| State Prescription Drug Monitoring Programs (PDMPs) | Most states mandate PDMP query before prescribing Schedule II-IV; real-time database of controlled substance prescriptions filled | Identifies patients receiving controlled substances from multiple prescribers (“doctor shopping”); required pre-prescribing step in most states |
| CDC Clinical Practice Guideline for Prescribing Opioids (2022) | Evidence-based recommendations: use lowest effective dose; reassess at 1–4 weeks; avoid concurrent opioid + benzodiazepine when possible; offer naloxone co-prescription | Updated in 2022 to address criticisms that the 2016 guideline contributed to undertreated pain; current standard of practice reference for opioid prescribing decisions |
| DEA Electronic Prescriptions for Controlled Substances (EPCS) | Allows electronic transmission of Schedule II prescriptions meeting DEA security requirements; mandatory in some states (e.g., NY) | Reduces prescription fraud; improves prescribing workflow and PDMP integration |
| Opioid Treatment Agreements / Patient Agreements | Many institutional policies require signed agreement outlining patient responsibilities (urine drug testing, single pharmacy, no early refills) before initiating long-term opioid therapy | Ethical and legal documentation; not required by federal law but common as a risk management tool |
For your 2–4 sentence section, a strong approach: name the DEA Schedule II classification and what it restricts (no refills, DEA registration), name your state’s PDMP requirement specifically, and reference the 2022 CDC guideline as the current evidence-based prescribing standard. That’s three policy-level points in two to three sentences, all accurate and specific.
Pain Assessment Tools — Which Ones to Know
The assignment asks you to address “the importance of assessment and assessment tools.” That means two things: why systematic pain assessment matters clinically, and which validated tools are used. Here are the ones most relevant to this assignment.
NRS — Numeric Rating Scale
0–10 scale of pain intensity. Fast, widely used, valid for self-report in cognitively intact adults. The most commonly used tool in acute and chronic pain settings. Limitation: measures intensity only, not character or functional impact.
CPOT — Critical Care Pain Observation Tool
Behavioral assessment for patients who cannot self-report (intubated, unconscious). Scores facial expression, body movements, muscle tension, and compliance with ventilator. Validated in ICU populations.
BPI — Brief Pain Inventory
Assesses pain intensity AND interference with function (sleep, mood, work, relationships). More comprehensive than NRS alone. Used in cancer pain, chronic pain research, and functional outcomes monitoring.
McGill Pain Questionnaire
Multidimensional: sensory, affective, and evaluative dimensions of pain using verbal descriptors. Short form (SF-MPQ-2) preferred in clinical settings. Particularly useful for characterizing neuropathic vs. nociceptive pain quality.
ORT — Opioid Risk Tool
5-item screening tool for estimating risk of aberrant opioid-related behavior before initiating opioid therapy. Scores personal/family history of substance abuse, age, history of depression or sexual abuse. Required by many institutional opioid prescribing protocols.
DN4 / Neuropathic Pain Scale
Discriminates neuropathic from nociceptive pain. DN4 questionnaire uses 10 items including burning, electric shock quality, tingling, and allodynia — score ≥4/10 indicates neuropathic component. Guides choice of anticonvulsant vs. NSAID therapy.
Why Assessment Matters Beyond Documentation
Assessment isn’t just regulatory box-checking. Systematic pain assessment drives drug selection (neuropathic pain → anticonvulsants; musculoskeletal spasm → muscle relaxants), determines dose titration, identifies inadequate treatment early, and provides the outcome data that justifies continuing, modifying, or discontinuing therapy. The 2022 CDC guideline explicitly states that pain assessments should evaluate pain severity, functional impact, and quality of life — not just an NRS number. For your essay section, connect the tools to clinical decision-making, not just documentation compliance.
Non-Pharmacological Pain Therapies
This section should demonstrate that you understand pain management as multimodal — not that pharmacotherapy is optional when pain is severe, but that non-pharmacological approaches reduce reliance on medication, address underlying drivers of pain that drugs can’t, and are sometimes superior for specific pain types.
| Therapy | Mechanism / Evidence Basis | Best For |
|---|---|---|
| Physical Therapy & Therapeutic Exercise | Reduces central sensitization; improves musculoskeletal function; promotes endogenous opioid release; addresses deconditioning cycle in chronic pain | Chronic low back pain, osteoarthritis, fibromyalgia, post-surgical rehabilitation |
| Cognitive Behavioral Therapy (CBT) | Modifies catastrophizing, fear-avoidance behaviors, and maladaptive pain responses; shown in RCTs to reduce pain intensity and improve function; effect sustained at 12-month follow-up in chronic pain populations | Chronic pain with psychological comorbidity; prevention of acute-to-chronic pain transition |
| TENS (Transcutaneous Electrical Nerve Stimulation) | Activates gate control mechanism at dorsal horn; activates endogenous opioid release at high-intensity settings; convenient, low-risk, patient-controlled | Localized neuropathic pain, musculoskeletal pain, post-operative analgesia adjunct |
| Mindfulness-Based Stress Reduction (MBSR) | 8-week structured program; fMRI studies show changes in pain-processing brain regions; reduces pain catastrophizing; Zeidan et al. (2016) demonstrated MBSR reduces pain intensity in chronic pain populations independent of opioid pathway activation | Chronic pain, cancer pain, fibromyalgia; patients who cannot tolerate pharmacotherapy |
| Acupuncture | Stimulates Aδ and C nerve fibers; modulates endogenous opioid, serotonin, and norepinephrine pathways; systematic reviews show modest but consistent effect for chronic back pain, neck pain, and OA | Chronic musculoskeletal pain, chemotherapy-induced neuropathy, headache prophylaxis |
| Heat / Cold Therapy | Heat reduces muscle spasm, increases tissue extensibility, and improves local circulation; cold reduces acute inflammation and slows nerve conduction velocity → reduces pain signal transmission | Acute musculoskeletal injury (cold first 48 hours), chronic muscle tension (heat), localized inflammatory pain |
For your 2–4 sentence section, select 3–4 of these, name them specifically, and note one thing about each — either its mechanism, its evidence level, or its best clinical indication. The goal is specificity, not an exhaustive list.
Common Errors in NU553 Unit 9 Submissions
| ❌ Error | Why It Costs You | ✓ The Fix |
|---|---|---|
| Pasting textbook paragraphs into the table cells | Instructions explicitly say “key words with bulleted content” — large paragraph blocks in Arial 10pt are unreadable and violate the formatting requirement | Use 3–5 bullet points per cell. Each bullet: one specific clinical fact. If you can’t say it in a line, split it into two bullets. |
| Confusing pharmacodynamics and pharmacokinetics | These are defined, distinct concepts. Mixing them up in the essay sections is a foundational pharmacology error | PD = what the drug does to the body (receptors, mechanisms, effects). PK = what the body does to the drug (absorption, distribution, metabolism, excretion). Know this cold before you write. |
| Vague legal/ethical content (“nurses must follow laws”) | The section is testing whether you know specific legal frameworks and can articulate real ethical tensions — not whether you endorse compliance | Name the Controlled Substances Act. Name your state PDMP. Articulate the specific ethical tension between undertreated pain and addiction risk. Cite the ORT or a patient agreement as a tool for navigating that tension. |
| Missing the “Monitoring / Goals / Assessment Scale” row in the table | This is the last and most clinical row — it’s also the one most frequently left as vague or incomplete, which directly costs rubric points | For each drug: name the specific assessment tool (NRS, CPOT, ORT, DN4), state a measurable goal (NRS ≤4, functional improvement at 2 weeks), and note any lab monitoring required (LFTs for acetaminophen, BMP for NSAIDs/gabapentin) |
| Choosing obscure or poorly documented drugs | If you pick a drug you can’t find in your textbook, your citations will be weak and your content may be inaccurate | Stick with the recommended drugs in this guide (acetaminophen, ibuprofen, morphine, gabapentin, cyclobenzaprine, dronabinol) — all are well-covered in Rosenthal & Burchum and supported by strong peer-reviewed literature |
| No verified external source for cannabis column | Cannabis as a pain management agent is an emerging evidence area — the assignment context implies current and emerging evidence should inform your content | Aviram & Samuelly-Leichtag (2017) published “Efficacy of Cannabis-Based Medicines for Pain Management” in Pain Physician — a peer-reviewed, accessible source for the cannabis column. Cite it with DOI. |
Final Checklist Before Submission
- Name and date filled in on the template
- All 9 essay headers bolded
- Each section: 2–4 sentences, not more
- Each table column: one specific drug named
- Table font: Arial 10pt throughout
- Monitoring row: specific tool + measurable goal for every drug
- Legal section: names at least one specific law or policy
- References in APA 7th edition on a separate reference page
- No large blocks of text in the table cells
- Spell-check completed
FAQs: NU553 Unit 9 Assignment
The Short Version: What This Assignment Wants From You
NU553 Unit 9 is testing whether you can take foundational pharmacology principles — pharmacodynamics, pharmacokinetics, mechanism of action — and apply them to a specific clinical domain (pain management) with enough precision and accuracy to demonstrate clinical competency. It’s not testing whether you can write long paragraphs. Every essay section should be tight, specific, and cited. Every table cell should be clinical information, not filler.
The drug choices in this guide give you a solid, well-documented set to work with. The legal and policy content above gives you the specific frameworks the rubric expects. The assessment tool section gives you the clinical instruments — not just the NRS, but the ORT, the DN4, the CPOT, the BPI — that distinguish a thorough response from a minimal one.
Work through one section at a time, verify every clinical claim against your textbook or a peer-reviewed source, and keep the table cells in Arial 10pt. That’s the whole assignment. For support at any stage, the team at Smart Academic Writing includes nursing faculty and pharmacology specialists who can help you get this done accurately and on time.